Ran Frenkel - EVP, Chief Dev. Officer at Karyopharm Therapeutics Inc.

Insider Transactions and Holdings

Class	Num Shares	Value	Price $	Transaction Date	Ownership	Underlying Class	Underlying Amount
Common Stock	168K	$138K	$0.82	Feb 28, 2022	Direct
Stock Option (right to buy)	90K			Feb 28, 2022	Direct	Common Stock

Showing 1 to 2 of 2 entries

Sym	Class	Transaction	%	Value $	* Price $	Shares	Shares After	Date	Ownership

* An asterisk sign (*) next to the price indicates that the price is likely invalid.